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Case Study
Siblings and Discordant Eligibility for
Gene Therapy Research: Considering
Parental Requests for Non-Trial
"Compassionate Use”
Jamie Webb1 , Lesha D Shah2 and Alison Bateman-House3
Abstract
Deciding whether to grant an expanded access request for a child whose sibling is enrolled in a gene therapy trial
involves a number of complex factors: considering the best interests of the child, the psychosocial and economic
impact on the family, and the concerns and obligations of researchers. Despite the challenges in coming to a substan-
tively fair outcome in cases of discordant eligibility, creating a procedurally fair decision-making process to adjudicate
requests is essential.
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Case
Peter, aged 6, and James, 3, both have Duchenne mus-
cular dystrophy (DMD), a life-limiting genetic disor-
der. James and Peter’s mother, Susan, who is active in
the US Duchenne community, learns about a Phase 2
clinical trial studying an experimental DMD gene ther-
apy. Susan enquires about enrolling her sons as trial
participants. The researchers inform her that Peter is
within the trial’s age range of eligibility, but James is
too young. Peter undergoes screening, is found to be
eligible and willing to participate, and, after Susan pro-
vides parental permission, is accepted into the trial.
Although participation in this trial will likely rule
Peter out from any future trials, gene therapy or oth-
erwise, Susan decides to enroll him. Susan then
requests access to the investigational gene therapy for
James via expanded access (EA). EA is a regulatory
pathway by which patients in the United States with
life-threatening or serious diseases or conditions for
which no satisfactory approved therapy options
are available and clinical trial participation is not pos-
sible can use experimental medical products outside of
a clinical trial, provided the biopharmaceutical
company developing the drug agrees to provide it and
conditional on Food and Drug Administration (FDA)
and institutional review board (IRB) approval. The
company developing the gene therapy has not estab-
lished how it will consider requests stemming from
siblings who are discordantly eligible to participate in
its trial.
Context
DMD is characterized by progressive muscular degener-
ation caused by alterations to the dystrophin protein,
which is needed to maintain the integrity of straited
muscle.1 It primarily affects boys. Most boys with
DMD present between the ages of 3 and 5; as such, it
is not uncommon for parents to have more than one child
before realizing the elder has a life-limiting genetic condi-
tion.2 Duchenne is an X-linked condition. Although 30%
of cases are caused by spontaneous mutations,3 it is usu-
ally passed from women who are carriers of the genetic
mutation. If a woman carries a mutation in the gene that
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encodes for her dystrophin, there is a 50% chance she will
pass on this gene to a child.4
DMD experimental gene therapies often use a viral
vector to introduce a working version of a gene that
codes for the production of dystrophin into a patient’s
cells .5 While clinical trials are in progress, there is cur-
rently no FDA approved gene therapy for Duchenne.
The interests of the ineligible child
Peter and James will experience progressive muscle
weakness, resulting in eventual loss of ambulation,
impaired pulmonary and cardiac function, and then
acute cardiac and respiratory failure, leading to early
death.2 The only treatments available are non-curative,
which can (in some subgroups of patients) delay pro-
gression rather than prevent it, or improve quality of
life and lifespan, for example non-invasive ventilation.6
However, there are risks inherent to experimental gene
therapies that may be considered untenable by a
parent, even considering this prognosis. Because gene
therapies are so new, their safety, effectiveness and
durability is not fully known.7 There have been several
deaths among gene therapy trial participants that
appeared to have directly resulted from the experimen-
tal intervention..8,9 Other gene therapy recipients have
suffered serious or life-threatening adverse events.10
Thus far, two experimental gene therapies being
tested for use against muscular dystrophy have resulted
in serious adverse events.11–13
Also, because optimal dosing has not yet been estab-
lished, there is no guarantee that James will receive a
high enough dose to provide him therapeutic benefit,
even if the intervention is found safe and effective. The
viral vector used to deliver the product will result in
recipients developing an immune response to that virus
that would preclude redosing at any level.14 Thus, even
if this investigational product fails, he will not get to try
it, or any other gene therapy that uses the same virus,
again. Even if James would assent to EA at this time if
offered it, his autonomy may not be best respected by
limiting his future options in the pursuit of uncertain
clinical benefit.
Age is relevant: if possible, it may be better for
James to wait to participate in a later-stage gene ther-
apy clinical trial – when more is known about dosing,
safety, and efficacy – or to wait until a gene therapy is
approved by the FDA. Furthermore, James’ ability to
understand what is being proposed will increase during
the process of waiting as he matures. However, the
benefits of waiting must be weighed against the fact
that the longer a child goes without adequate dystro-
phin, the more irreversible damage accumulates.
By waiting, there is also a risk of James encountering
the virus used to deliver the gene therapy through
environmental exposure and becoming ineligible to
use any product delivered via that virus.
Psychosocial and economic issues for
family and caregivers
The atmosphere of hope and expectation that surround
gene therapy trials15–17 may increase the predisposition
of families to have their children enrolled in these trials
or to find non-trial avenues to receive the gene therapy
if they are ineligible. Participation in a clinical trial
almost invariably places significant social and econom-
ic burdens on families, and enrolling can mean signif-
icant opportunity costs. Gene therapy trials, which can
entail several long stays at trial sites, may require relo-
cating all or part of a family to a new location, with the
stress and logistical challenges this entails. Non-trial
access would involve at least some of these opportunity
costs, as the intervention must be given in a controlled
and monitored manner.
In this case, these challenges are heightened. Both
boys are too young to meaningfully make their own
treatment decisions, though efforts should be made to
help them understand their options to the extent pos-
sible. After receiving the experimental intervention,
Peter would likely shed the viral vector for an indeter-
minate amount of time. As such, he could infect James,
who might then develop an immunity to the vector,
rendering him incapable of using any interventions
administered by this vector. Prudent caution for
James would therefore include isolation from Peter
for an unknown period of time, in order to best
ensure James’ future ability to receive a gene therapy.
Such separation need not happen if both boys were to
receive the gene therapy at the same time, Peter
through the trial and James through EA. However,
‘at the same time’ may be hard to achieve, particularly
given the fact that the volume of gene therapy product
being produced is quite modest and trials are designed
to accommodate only small numbers of participants.
If only Peter received the intervention at this time, it
would be extremely challenging to separate the boys,
particularly if Susan is their sole caregiver. Even if
James and Peter have another caregiver, non-
simultaneous administration would entail separation
of the family. In either case, severe financial and psy-
chosocial burdens may be incurred, especially if the
young children do not understand why the family
must be separated. Trial sponsors often provide
financial support of costs directly associated with the
trial to participants’ families, but it is unclear if a
sponsor would be willing to do likewise for a child
receiving the experimental product outside of a
research clinical trial.
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Additionally, if the EA request for James is refused,
there is the possibility that Susan and/or Peter will feel
guilt for Peter receiving a potentially life-altering interven-
tion at a time when it is unavailable to James. As James
matures, he may feel envy or resentment for not having
had the same opportunity as his brother. Alternatively, if
Peter does not benefit from the trial and James is later
able to receive an improved version, their relationship
may have aspects of jealousy and/or survivor’s guilt. If
James develops immunity to the virus used as a vector in
Peter’s trial, there may be a sense of guilt on Peter or
Susan’s part, even though James’ viral exposure may
not have been trial-related. Also, James’ age and early
stage of development means that his separation from
Susan, as she accompanies Peter through the trial,
comes with the risk of affecting his caregiver attachment,
stress levels, and potentially even brain structure.18
Alternatively, if James received the intervention
through EA, the family may experience feelings of
resentment from others in the DMD community.
Given the fact that there is far more interest in receiv-
ing gene therapies than there are available enrollment
opportunities in trials, how might the relationship
between Susan and other parents change if James
receives the intervention through EA because his
brother was enrolled in the trial, while other children
are unable to obtain it? Unless the intervention is avail-
able on an equitable basis via EA for all who desire it,
are physically eligible to receive it (e.g., not immune),
and are unable to participate in the trial, it seems likely
that there will be some perceptions of unfairness, par-
ticularly in a closely-knit rare disease community where
it is unlikely that Susan would be able to conceal news
of James’ treatment via EA. Yet large scale EA for gene
therapy – enough to provide the experimental interven-
tion to all who desire it - is unlikely.19
Concerns for researchers
Gene therapy production is currently extremely expen-
sive and entails a complex manufacturing process.
There would be severe logistical challenges in increas-
ing production sufficiently to develop product above
that necessary for a clinical trial.19 Indeed, such addi-
tional production may be simply impossible, given
demand currently outweighs the capacity of gene ther-
apy manufacturers.
EA, by law, may be offered only to patients ineligi-
ble for clinical trial participation and therefore should
not undermine trial enrollment.20 However, offering
EA may reduce an already limited number of consum-
ers for approved future treatments for such rare genetic
diseases, particularly in light of ongoing immunogenic-
ity concerns that would render the recipient of an inter-
vention unable to try others that use the same viral
vector. This provides a financial disincentive for the
company to offer EA. Moreover, companies may fear
that side effects in an EA recipient will result in nega-
tive publicity, potentially leading investors to back
away and to place their current and future trials in
jeopardy with regard to enrollment.
Nevertheless, sponsors have responsibilities in the
case of siblings with the same condition who are dis-
cordantly eligible to participate in a gene therapy trial.
First, they must practice epistemic humility in convey-
ing to families the extent of the uncertainty surround-
ing gene therapy, on issues like risk, redosing, and
immune response. Moreover, researchers must provide
counseling support to families, as is often offered with
other serious medical procedures such as organ dona-
tion.21 Families could also be placed in touch with
(willing) previous trial participants, who may be able
to offer emotional support and advice.
Finally, in 2010, the Committee on Drugs and
Committee on Pediatric Research described the poten-
tial risks involved in pediatric studies as including:
“separation from parents, family, or friends; effects
on growth and development.”22 By enrolling Peter in
a trial, the researchers are also imposing these risks on
James, as well as the risk of viral exposure and its
consequences. Since the Common Rule, which governs
human subjects research conducted under the auspices
of certain US agencies but is frequently voluntarily
applied to all human subjects research regardless of
funding source, demands that greater than minimal
risk research in children carry some potential for
direct benefit,23 it could be argued the sponsor is obli-
gated to provide possible benefit to James. This benefit
could plausibly be access to the intervention via EA.
Conclusion: Procedural and
substantive fairness
Although it is hard to say what would be a substantively
fair outcome in sibling cases, it is comparatively easier to
create a procedurally fair decision-making process to
adjudicate EA requests. Procedural and substantive fair-
ness are distinct ideas. Consider the difference between a
lottery and a criminal trial. A lottery is procedurally fair
if everyone is able to enter, everyone knows how the lots
are drawn, and the draw is done transparently so all can
witness that the process has not been perverted. That
says nothing, however, as to whether drawing lots is a
substantively fair procedure by which to allocate a good.
By contrast, the procedural elements of a trial, for exam-
ple the right to a defense, are designed to generate cer-
tain substantively fair outcomes: the determination of
guilt and the acquittal of the innocent.
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A number of the psychosocial issues raised in this
paper may be mitigated if research sponsors produce
clear, publicly available policies concerning how and by
which criteria sibling requests would be considered: a
transparent, procedurally fair process that researchers
and families are aware of before cases become a reality.
At this time, it is believed that only one company (PTC
Therapeutics) has created such a policy for an investi-
gational product, and it was not in the context of a
gene therapy trial.24
This is not to say that concerns of substantive fair-
ness – for example, whether it is fair for a sibling to get
EA but not an unrelated child, particularly if the latter
might be anticipated to derive more clinical benefit
from the intervention – are unimportant. But the fac-
tors that go into such judgments are complex and
deeply contextual. Provided processes are designed
with engagement from all stakeholders, and critically
engage with the ethical issues raised in this commen-
tary, then the procedurally fair policy that results from
this deliberation could guide researchers in responding
to Susan’s request for EA access for James. The
response may be refusal or acceptance, but it needs to
be arrived at by a procedurally fair process.
If the decision is to make the investigational product
available outside of a clinical trial for the trial-ineligible
sibling, those involved must then assume responsibility
for performing the procedure in an ethical manner,
including securing pediatric assent (as possible) and
parental permission, and ensuring it is carried out in
accordance with all relevant oversight bodies, including
the FDA and the IRB.
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